alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Disease mechanisms in lab and animal studies

1,352 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science 1991-07-12 Vascular contributions

    The secondary structures in solution of the synthetic, naturally occurring, amyloid beta peptides, residues 1 to 42 [beta (1-42)] and beta (1-39), and related fragments, beta (1-28) and beta (29-42), have been studied by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy.

  2. Cleavage of amyloid beta peptide during constitutive processing of its precursor

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science (New York, N.Y.) 1990-06-01 Risk genes beyond APOE

    The amyloid beta peptide (A beta P) is a small fragment of the much larger, broadly distributed amyloid precursor protein (APP).

  3. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science (New York, N.Y.) 1990-04-01 Risk genes beyond APOE

    The beta-amyloid protein (beta/A4), derived from a larger amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease.

  4. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science (New York, N.Y.) 1989-07-01 Risk genes beyond APOE

    Amyloid deposition in senile plaques and the cerebral vasculature is a marker of Alzheimer's disease.

  5. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Nature 1988-10-01 Disease mechanisms

    The clinical manifestations of AIDS (acquired immune deficiency syndrome) often include neuropsychiatric and neurological deficits, including early memory loss and progressive dementia.

  6. Conservation of Brain Amyloid Proteins in Aged Mammals and Humans with Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science 1987-02-20 Vascular contributions

    The formation of clusters of altered axons and dendrites surrounding extracellular deposits of amyloid filaments (neuritic plaques) is a major feature of the human brain in both aging and Alzheimer's disease.

  7. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Nature 1980-11-01 Brain tissue and pathology

    Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques.

  8. Activation of neurogenesis improves amyloid-β pathology and cognitive function through AMP kinase signaling in Alzheimer’s disease model mice

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cell reports 2025-12-26 Down syndrome and Alzheimer's

    Adult hippocampal neurogenesis declines with aging and in neurological disorders, leading to cognitive impairment.

  9. Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cell death & disease 2025-07-18 Down syndrome and Alzheimer's

    Brain derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) play crucial roles in neuronal development, synaptic transmission, and neuroplasticity.

  10. A High-Throughput Drug Screening Assay for Anti-Tau Aggregation Using Split GFP and Flow Cytometry

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Scientific reports 2025-06-18 Drug development

    Tau protein aggregation is a hallmark of neurodegenerative diseases, including Alzheimer's disease, making the development of anti-aggregation therapeutics a critical area of research.

  11. Tau-targeting therapies for Alzheimer disease: current status and future directions

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature reviews. Neurology 2023-10-24 Drug development

    Alzheimer disease (AD) is the most common cause of dementia in older individuals.

  12. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature biotechnology 2022-06-02 Brain scans and imaging

    Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new delivery solutions are needed to target additional organs.

  13. Oxidative stress: The core pathogenesis and mechanism of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Ageing research reviews 2022-04-05 Disease mechanisms

    As the number of patients with Alzheimer's disease (AD) increases, it brings great suffering to their families and causes a heavy socioeconomic burden to society.

  14. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Chemical Society reviews 2022-01-24 Drug development

    Converging evidence continues to point towards Tau aggregation and pathology formation as central events in the pathogenesis of Alzheimer's disease and other Tauopathies.

  15. Current Status of Clinical Trials on Tau Immunotherapies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Drugs 2021-06-08 Drug development

    Tau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical trials for Alzheimer's disease (AD) and other tauopathies.

  16. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Science translational medicine 2021-05-01 Drug development

    Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD).

  17. Reducing acetylated tau is neuroprotective in brain injury

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cell 2021-04-13 Biomarkers

    Traumatic brain injury (TBI) is the largest non-genetic, non-aging related risk factor for Alzheimer's disease (AD).

  18. Fluorescent Determination of Butyrylcholinesterase Activity and Its Application in Biological Imaging and Pesticide Residue Detection

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. ACS Sensors 2021-01-27 Risk factors

    Butyrylcholinesterase (BChE) is an essential human cholinesterase relevant to liver conditions and neurodegenerative diseases, which makes it a pivotal biomarker of health.

  19. The β-Secretase BACE1 in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biological psychiatry 2020-02-13 Risk genes beyond APOE

    BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized in 1999.

  20. Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neurology and neuroscience 2017-02-28 Treatments

    Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits.

  21. Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca 2+ -Handling Deficits in Alzheimer's Disease Models

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. NPJ aging and mechanisms of disease 2016-09-22 Biomarkers

    Alzheimer's Disease (AD) is an age-related neurodegenerative disorder in which aggregation-prone neurotoxic amyloid β-peptide (Aβ) accumulates in the brain.

  22. Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer’s Disease Phenotypes

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. PLoS ONE 2016-09-13 Risk genes beyond APOE

    The dismal success rate of clinical trials for Alzheimer's disease (AD) motivates us to develop model systems of AD pathology that have higher predictive validity.

  23. Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cell discovery 2016-08-23 Biomarkers

    Mutations in the amyloid precursor protein (APP) gene and the aberrant cleavage of APP by γ-secretase are associated with Alzheimer's disease (AD).

  24. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of Experimental Medicine 2016-08-08 Mild cognitive impairment

    Parkinson's disease (PD) is characterized by the progressive appearance of intraneuronal Lewy aggregates, which are primarily composed of misfolded α-synuclein (α-syn).

  25. DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in behavioral neuroscience 2016-06-03 Down syndrome and Alzheimer's

    Down syndrome (DS) is one of the leading causes of intellectual disability, and patients with DS face various health issues, including learning and memory deficits, congenital heart disease, Alzheimer's disease (AD), leukemia, and cancer, leading to huge medical and social costs.

From across this topic

10 of the 1,352 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics